Ensign Peak Advisors
ATRA icon

Ensign Peak Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Ensign Peak Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,296
Closed -$217K – 1820
2022
Q3 		$217K Sell
2,296
-6,805
-75% -$764K ﹤0.01% 1849
2022
Q2 		$1.77M Buy
9,101
+2,558
+39% +$418K ﹤0.01% 850
2022
Q1 		$1.52M Buy
6,543
+5,826
+813% +$1.86M ﹤0.01% 995
2021
Q4 		$282K Sell
717
-2,032
-74% -$855K ﹤0.01% 1836
2021
Q3 		$1.23M Buy
+2,749
New +$985K ﹤0.01% 1346
2021
Q1 		– Sell
-1,996
Closed -$979K – 1830
2020
Q4 		$979K Hold
1,996
– – ﹤0.01% 1411
2020
Q3 		$647K Buy
+1,996
New +$680K ﹤0.01% 1456

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ensign Peak Advisors's ATRA Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 2,296 shares — an estimated $217K sold.

Ensign Peak Advisors first reported a position in ATRA in Q3 2020 and held it in 7 quarters. The position peaked at $1.77M in Q2 2022. 138 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 2,296 Atara Biotherapeutics shares in Q4 2022, an estimated $217K.
  • Ensign Peak Advisors first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 7 quarters.
  • Ensign Peak Advisors's Atara Biotherapeutics position peaked at $1.77M in Q2 2022.
  • 138 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.